Increased expression of fatty acid synthase in human aberrant crypt foci: possible target for colorectal cancer prevention.
Aberrant crypt foci (ACF), the earliest identified monoclonal lesions in the colon, provide insights into changes that promote and/or accompany the transformation of normal colonic epithelial cells to colorectal cancer. Fatty acid synthase (FAS), the primary enzyme involved in de novo lipogenesis from carbohydrates, is expressed at low levels in most normal human tissues but is elevated in several human neoplasms including colorectal adenomas and carcinomas. To determine if this pathway is altered even earlier in colorectal tumorigenesis, 35 human ACF from 21 patients were evaluated for the immunohistochemical expression of FAS. Sections of colon cancer served as positive controls, and normal colonic mucosa distant from cancer or ACF served as negative controls. FAS expression was increased in 30 (86%) ACF compared with that in adjacent normal colonic mucosa. The expression of FAS in ACF was not related to the degree of dysplasia or to the number of crypts in the ACF. The over expression of FAS in a high proportion of ACF suggests that this enzyme plays an important role very early in colorectal tumorigenesis and may be a target for chemoprevention.
Department of Pathology and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106-7288, USA.
Kathleen E
KE
Kearney
Thomas G
TG
Pretlow
Theresa P
TP
Pretlow
D000369:Aged, 80 and over; D003106:Colon / Q000201:enzymology* / Q000473:pathology; D015179:Colorectal Neoplasms / Q000201:enzymology* / Q000473:pathology / Q000517:prevention & control*; D054890:Fatty Acid Synthase, Type I / Q000378:metabolism*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D011230:Precancerous Conditions / Q000201:enzymology* / Q000473:pathology; D011379:Prognosis
C518729:FASN protein, human; D054890:Fatty Acid Synthase, Type I